Biomind Labs Inc. (BMNDF)
OTCMKTS · Delayed Price · Currency is USD
0.105
0.00 (0.00%)
Apr 28, 2026, 9:30 AM EST

Biomind Labs Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Selling, General & Admin
0.420.380.661.761.45
Upgrade
Research & Development
-0.020.310.570.57
Upgrade
Operating Expenses
0.850.40.992.933.43
Upgrade
Operating Income
-0.85-0.4-0.99-2.93-3.43
Upgrade
Interest Expense
-0.07-0.03-0.16-0-0
Upgrade
Currency Exchange Gain (Loss)
0.02-0.02-0.03-0.05-0.06
Upgrade
Other Non Operating Income (Expenses)
-0.020.19-0.01--0.84
Upgrade
EBT Excluding Unusual Items
-0.92-0.27-1.19-2.99-4.33
Upgrade
Gain (Loss) on Sale of Assets
0.07----
Upgrade
Other Unusual Items
-0---
Upgrade
Pretax Income
-0.85-0.26-1.19-2.99-4.33
Upgrade
Net Income
-0.85-0.26-1.19-2.99-4.33
Upgrade
Net Income to Common
-0.85-0.26-1.19-2.99-4.33
Upgrade
Shares Outstanding (Basic)
7876757572
Upgrade
Shares Outstanding (Diluted)
7876757572
Upgrade
Shares Change (YoY)
1.87%1.85%-3.75%76.71%
Upgrade
EPS (Basic)
-0.01-0.00-0.02-0.04-0.06
Upgrade
EPS (Diluted)
-0.01-0.00-0.02-0.04-0.06
Upgrade
Free Cash Flow
-0.07-0.35-0.77-2.15-2.17
Upgrade
Free Cash Flow Per Share
-0.00-0.01-0.01-0.03-0.03
Upgrade
EBITDA
-0.84-0.4-0.98-2.93-3.4
Upgrade
D&A For EBITDA
00.010.010.010.03
Upgrade
EBIT
-0.85-0.4-0.99-2.93-3.43
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.